Lipitor (Atorvastatin) News and Research

RSS
Atorvastatin (INN) (Lipitor, Pfizer), is a member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes through anti-inflammatory and other mechanisms. Atorvastatin inhibits HMG-CoA reductase, the rate-determining enzyme located in hepatic tissue that produces mevalonate, a small molecule used in the synthesis of cholesterol and other mevalonate derivatives. This lowers the amount of cholesterol produced which in turn lowers the total amount of LDL cholesterol. Atorvastatin was first synthesized in 1985 by Bruce Roth while working at Parke-Davis Warner-Lambert Company (now Pfizer). With 2006 sales of US$12.9 billion, Lipitor is the largest-selling drug in the world.
Statins reduce risk of stroke and heart attack

Statins reduce risk of stroke and heart attack

Effect of Torcetrapib on the progression of coronary atherosclerosis

Effect of Torcetrapib on the progression of coronary atherosclerosis

Addition of torcetrapib to statin therapy has no benefit for atherosclerosis progression

Addition of torcetrapib to statin therapy has no benefit for atherosclerosis progression

Atorvastatin shows potential as a new treatment for spinal cord injuries

Atorvastatin shows potential as a new treatment for spinal cord injuries

Lipitor given the green light for more heart risk patients

Lipitor given the green light for more heart risk patients

Study compares Lipitor with Simvastatin

Study compares Lipitor with Simvastatin

Danish court injunction prohibits sale of generic Lipitor

Danish court injunction prohibits sale of generic Lipitor

High-dose Lipitor therapy cuts risk of hospitalizations for heart failure

High-dose Lipitor therapy cuts risk of hospitalizations for heart failure

Statins show extra benefit in raising "good" HDL cholesterol levels

Statins show extra benefit in raising "good" HDL cholesterol levels

TV ads for drugs high on the emotions but low on facts

TV ads for drugs high on the emotions but low on facts

Favorable decision for Ranbaxy on Atorvastatin patent in Canada

Favorable decision for Ranbaxy on Atorvastatin patent in Canada

Pfizer stops all Torcetrapib trials

Pfizer stops all Torcetrapib trials

Pfizer provides opinion on European Lipitor patent

Pfizer provides opinion on European Lipitor patent

Spanish patent victory favoring Ranbaxy on Atorvastatin unaffected

Spanish patent victory favoring Ranbaxy on Atorvastatin unaffected

Austrian patent office rules in Pfizer's Favor for Lipitor patent

Austrian patent office rules in Pfizer's Favor for Lipitor patent

Now OK to get prescription drugs from Canada, but is it really?

Now OK to get prescription drugs from Canada, but is it really?

Combating generics: pharmaceutical brand defense for 2007

Combating generics: pharmaceutical brand defense for 2007

More physicians now visit web sites to find information on brand-name prescription drugs

More physicians now visit web sites to find information on brand-name prescription drugs

Ranbaxy invalidates Pfizer's 281 patent in Holland

Ranbaxy invalidates Pfizer's 281 patent in Holland

Dutch court upholds Lipitor patent

Dutch court upholds Lipitor patent